Dynavax Technologies | DVAX - Ordinary Share Capital


Dynavax Technologies reported $117.23M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Adma Biologics USD 236.62M 242K Dec/2024
Amgen USD 538M 300K Sep/2025
AstraZeneca USD 1.55B 1.16B Sep/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Dynavax Technologies USD 117.23M 117.11M Jun/2025
Gilead Sciences USD 1.24B 0 Sep/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
TG Therapeutics USD 155.21M 2.81M Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025